| Cat.No. | Name | Information |
|---|---|---|
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M1810 | AZD5438 | AZD5438 is a novel, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively). |
| M1800 | JNJ-7706621 | JNJ-7706621 is a dual cell cycle inhibitor with activity against cyclin-dependent kinases (CDK1, 2, 3, 6) with an IC50 of 3-175 nM and Aurora kinases (A and B) with an IC50 of 11-15 nM respectively. |
| M1740 | R547 | R547 is a potent and selective ATP-competitive CDK inhibitor. |
| M54712 | PF-07224826 | PF-07224826 is a CDK2/4/6 inhibitor. |
| M54711 | INCB123667 | INCB123667 is a CDK2 inhibitor. |
| M54709 | Q901 | Q901 is a CDK7 inhibitor for tumor-related studies. |
| M54708 | NUV-422 | NUV-422 is a CDK2/4/6 inhibitor that can be used in studies related to malignant gliomas. |
| M54707 | INX-315 | INX-315 is an orally potent and selective CDK2 inhibitor that induces cell cycle arrest in G1 phase. INX-315 also induces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in a xenograft mouse model.INX-315 can be used in cancer-related studies. |
| M54706 | GTAEXS-617 | GTAEXS-617 is a highly selective small molecule non-covalent CDK7 inhibitor. |
| M54705 | BLU-222 | BLU-222 is a best-in-class, oral, potent and selective CDK2 inhibitor. |
| M54704 | AZD8421 | AZD8421 is a selective CDK2 inhibitor (IC50=9 nM) with selectivity for CDK1, CDK4 and CDK6. AZD8421 can target CDK2 and can be used in tumor-related studies. |
| M54632 | XPW1 | XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity. |
| M53361 | [pThr3]-CDK5 Substrate | [pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. |
| M53360 | Cdk2/Cyclin Inhibitory Peptide I | Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner. |
| M53359 | PSTAIR | PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control. |
| M49519 | NSC693868 | NSC693868 is a selective inhibitor of CDK1 and CDK5 with IC50s of 600 nM and 400 nM, respectively. |
| M49517 | K00546 | K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. |
| M49516 | Indirubin-5-sulfonate | Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. |
| M49515 | Indirubin-3'-monoxime-5-sulphonic acid | Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and GSK-3β with IC50s of 5 nM, 7 nM, and 80 nM, respectively. |
| M49514 | GSK-3/CDK5/CDK2-IN-1 | GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
